These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 1313200)

  • 21. SD-3212, a new class I and IV antiarrhythmic drug: a potent inhibitor of the muscarinic acetylcholine-receptor-operated potassium current in guinea-pig atrial cells.
    Hara Y; Nakaya H
    Br J Pharmacol; 1995 Nov; 116(6):2750-6. PubMed ID: 8591000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium channel blockers in the treatment of ventricular arrhythmias: different effects in the normal, ischaemic or failing heart?
    Haverkamp W; Hindricks G; Fechtrup C; Borggrefe M; Breithardt G
    Eur Heart J; 1991 Dec; 12 Suppl F():10-7. PubMed ID: 1666550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beta-blockers as antiarrhythmic agents.
    Zicha S; Tsuji Y; Shiroshita-Takeshita A; Nattel S
    Handb Exp Pharmacol; 2006; (171):235-66. PubMed ID: 16610347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [To the mechanisms of antiarrhythmic action of Allapinine].
    Vakhitova IuV; Farafontova EI; Khisamutdinova RIu; Iunusov VM; Cypasheva IP; Iunusov MS
    Bioorg Khim; 2013; 39(1):105-16. PubMed ID: 23844512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of Proarrhythmic Effects of Potassium Channel Blockers.
    Skibsbye L; Ravens U
    Card Electrophysiol Clin; 2016 Jun; 8(2):395-410. PubMed ID: 27261830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Basic cardiac electrophysiology and mechanisms of antiarrhythmic agents.
    Perry RS; Illsley SS
    Am J Hosp Pharm; 1986 Apr; 43(4):957-74. PubMed ID: 2871752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Electrophysiologic basis for arrhythmias in ischemic heart disease.
    Lazzara R; Scherlag BJ
    Am J Cardiol; 1984 Feb; 53(5):1B-7B. PubMed ID: 6364766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of alterations in refractoriness and conduction in the genesis of reentrant arrhythmias. Implications for antiarrhythmic effects of class III drugs.
    Wit AL; Coromilas J
    Am J Cardiol; 1993 Nov; 72(16):3F-12F. PubMed ID: 8237828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Vaughan Williams class IV antiarrhythmic drugs].
    Horie M; Washizuka T; Ikeguchi S; Sasayama S
    Nihon Rinsho; 1996 Aug; 54(8):2132-7. PubMed ID: 8810788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers.
    Fedida D; Orth PM; Hesketh JC; Ezrin AM
    J Cardiovasc Electrophysiol; 2006 May; 17 Suppl 1():S71-S78. PubMed ID: 16686685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis, electrophysiological properties and analysis of structural requirements of a novel class of antiarrhythmic agents with potassium and calcium channel blocking properties.
    Nadler G; Faivre JF; Forest MC; Cheval B; Martin M; Souchet M; Gout B; Bril A
    Bioorg Med Chem; 1998 Nov; 6(11):1993-2011. PubMed ID: 9881092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac ion channels and mechanisms for protection against atrial fibrillation.
    Grunnet M; Bentzen BH; Sørensen US; Diness JG
    Rev Physiol Biochem Pharmacol; 2012; 162():1-58. PubMed ID: 21987061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
    Bril A; Gout B; Bonhomme M; Landais L; Faivre JF; Linee P; Poyser RH; Ruffolo RR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):637-46. PubMed ID: 8632331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The antiarrhythmic actions of bisaramil and penticainide result from mixed cardiac ion channel blockade.
    Pugsley MK; Hayes ES; Saint DA; Walker MJA
    Biomed Pharmacother; 2019 Mar; 111():427-435. PubMed ID: 30594781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proarrhythmic response to sodium channel blockade. Theoretical model and numerical experiments.
    Starmer CF; Lastra AA; Nesterenko VV; Grant AO
    Circulation; 1991 Sep; 84(3):1364-77. PubMed ID: 1653123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular charge associated with antiarrhythmic actions in a series of amino-2-cyclohexyl ester derivatives.
    Pugsley MK; Yong SL; Goldin AL; Hayes ES; Walker MJA
    Eur J Pharmacol; 2019 Feb; 844():241-252. PubMed ID: 30571955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacology of antiarrhythmic drugs.
    Capucci A; Aschieri D; Villani GQ
    Drugs Aging; 1998 Jul; 13(1):51-70. PubMed ID: 9679209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells.
    Gwilt M; Arrowsmith JE; Blackburn KJ; Burges RA; Cross PE; Dalrymple HW; Higgins AJ
    J Pharmacol Exp Ther; 1991 Jan; 256(1):318-24. PubMed ID: 1988662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiarrhythmic agents and proarrhythmia.
    Chaudhry GM; Haffajee CI
    Crit Care Med; 2000 Oct; 28(10 Suppl):N158-64. PubMed ID: 11055685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro electrophysiological mechanisms for antiarrhythmic efficacy of resveratrol, a red wine antioxidant.
    Chen WP; Su MJ; Hung LM
    Eur J Pharmacol; 2007 Jan; 554(2-3):196-204. PubMed ID: 17107672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.